Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

NCT06951841 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Liposome Irinotecan
DRUG: Platinum
DRUG: Tislelizumab
DRUG: Anlotinib

Sponsor

China Medical University, China